Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ruben S.A. Goedegebuure"'
Autor:
Arantza Farina Sarasqueta, Annemieke Cats, Nicole Ct Grieken, Sarah Derks, Jurriën Stiekema, Rosa T. van der Kaaij, Johanna W. van Sandick, Victor L. J. L. Thijssen, Leonie K. de Klerk, Ruben S.A. Goedegebuure, Aaron R. Thorner, Roy L. J. van Wanrooij, Donald L. van der Peet, Manon van Engeland, Adam J. Bass, Maarten A J M Jacobs, Henk M.W. Verheul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29f0be064972773d9ee02e09b00b1aaa
https://doi.org/10.1002/1878-0261.12907/v2/response1
https://doi.org/10.1002/1878-0261.12907/v2/response1
Autor:
Tanja D. de Gruijl, John B. A. G. Haanen, Ruben S.A. Goedegebuure, Metin Tascilar, Charlotte M. Huijts, Hans J. van der Vliet, Paul Hamberg, Carla M.L. van Herpen, Sinéad M. Lougheed, Henk M.W. Verheul, Inge M. Werter
Publikováno v:
Cancer Immunology Immunotherapy, 68, 319-329
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, 68(2), 319-329. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 2, pp. 319-329
Huijts, C M, Werter, I M, Lougheed, S M, Goedegebuure, R S, van Herpen, C M, Hamberg, P, Tascilar, M, Haanen, J B, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma ', Cancer Immunology, Immunotherapy, vol. 68, no. 2, pp. 319-329 . https://doi.org/10.1007/s00262-018-2248-3
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, 68(2), 319-329. Springer Science and Business Media Deutschland GmbH
Cancer Immunology Immunotherapy, 68, 2, pp. 319-329
Huijts, C M, Werter, I M, Lougheed, S M, Goedegebuure, R S, van Herpen, C M, Hamberg, P, Tascilar, M, Haanen, J B, Verheul, H M, de Gruijl, T D, van der Vliet, H J & Dutch WIN-O Consortium 2019, ' Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma ', Cancer Immunology, Immunotherapy, vol. 68, no. 2, pp. 319-329 . https://doi.org/10.1007/s00262-018-2248-3
Background: For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae8fdb5bbd71bdebabc2536636937a5e
http://hdl.handle.net/2066/202111
http://hdl.handle.net/2066/202111
Autor:
Henk W.R. Schreuder, Sebastiaan Veersema, Frank J.M. Broekmans, Ruben S.A. Goedegebuure, Juliënne A. Janse
Publikováno v:
Journal of Minimally Invasive Gynecology. 20:775-782
Study Objective To assess the learning curve using a virtual reality simulator for hysteroscopic sterilization with the Essure method. Design Prospective multicenter study (Canadian Task Force classification II-2). Setting University and teaching hos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f25a909ade45124d555fe89271775e4
https://doi.org/10.1016/j.jmig.2013.04.016
https://doi.org/10.1016/j.jmig.2013.04.016
